TMCnet News

Welcome To Stock Hunter!! Sign Up Today!! GLER,CCTR,FNMA,BHWX,MLSS,AGEN
[July 27, 2010]

Welcome To Stock Hunter!! Sign Up Today!! GLER,CCTR,FNMA,BHWX,MLSS,AGEN


(M2 PressWIRE Via Acquire Media NewsEdge) Stock Hunter PRESENTS : (OTCBB: GLER) Global Earth Energy, Inc., (OTCBB: CCTR) China Crescent Enterprises, Inc., (OTCBB: FNMA) Fannie Mae, (OTCBB: BHWX) Black Hawk Exploration Inc., (OTCBB: MLSS) Milestone Scientific Inc., (NASDAQ: AGEN) Antigenics, Inc.



www.Stockhunter.us To sign up for our free Profiles & Alerts :: visit http://www.StockHunter.us Email us!! [email protected] ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: GLER - Global Earth Energy, Inc.) LATEST NEWS!! Global Earth Energy Receives Dealer Contracts Valued at $3 Million Total Revenues Expected to Top $8.5 Million in 2010 WILMINGTON, NC, Jul 27, 2010 -- Global Earth Energy, Inc. (OTCBB: GLER) announced that its wholly owned subsidiary RCI Solar, Inc., a North American provider of renewable energy products and services, has received commitments totaling $3 Million in solar energy product sales from its dealership network for accelerated delivery in 2010.

"In just six short months, our dealers have accounted for over $3 million in contractual sales. With a strong pipeline of additional contracts, RCI is on track to achieve record sales growth this year. We expect to generate total revenues of approximately $8.5 million to $10 million in 2010," said Mel Dick, president of RCI Solar, Inc.


"A well-established dealership network provides the expert implementation, installation and maintenance of all our systems. New business referrals from our dealerships can lead to additional revenue upside potential in the near future," said Syd Harland, CEO of Global Earth Energy, Inc.

About Global Earth Energy, Inc.

Through its subsidiary RCI Solar, Inc., Global Earth Energy, Inc. provides renewable energy products and services to residential and commercial markets in North America. The Company sells complete turnkey renewable energy solutions based on three core products: Solar Domestic Hot Water, Solar Photo Voltaic (PV) Panels and AQUA III Heating & Cooling System. Along with these products, RCI Solar supplies a wide variety of fan convectors, solar storage tanks, controls, inverters, and ancillaries from its headquarters in Vancouver, British Columbia, Canada.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: CCTR - China Crescent Enterprises, Inc.) LATEST NEWS!! China Crescent Announces Sale of Proprietary GPS Tracking Devices Into East Africa DALLAS, TX, Jul 27, 2010 -- China Crescent Enterprises, Inc. (OTCBB: CCTR) today announced the Company's original design manufacturing (ODM) subsidiary, Shenzhen Newbao Technology Co. Ltd., recently completed the sale of its proprietary GPS tracking devices to a confidential ICT systems integration firm headquartered in Nairobi, Kenya. China Crescent has been working diligently with the NewMarket Greenfield Partnership Program to expand its business by offering high quality, affordable technology solutions from China into the growing economies of East Africa. China Crescent's ODM subsidiary manufactures custom wireless products and is based in Shenzhen, China. The Company expects to complete subsequent sales of GPS tracking devices in the region based on initial customer satisfaction. Earlier this year, China Crescent also announced a $1.6 million purchase order for custom Wi-Fi equipment received from a Japanese client as part of an overall $160 million letter of intent commitment over the next three years that is subject to the performance of the initial order.

China Crescent is a systems integration service provider of brand name technologies operating primarily in China that reported $45 million in profitable annual revenue in 2009. China Crescent recently reported a more than 100% increase in first quarter revenue to nearly $15 million compared to the same period in 2009. Notably, net income increased more than 480% to approximately $657,000 versus the same period in 2009. The Company's recent expansion into additional lines of business in China, including outsourcing services and original design manufacturing (ODM), has contributed to the growth.

Sign Up to Receive Regular China Crescent Investor Updates China Crescent sends regular email updates to its opt-in, permission-based email database. Interested investors can easily, safely and quickly register to receive these communications directly on the corporate website homepage (www.chinacrescent.com). Recipients can manage their own email contact profile and safely unsubscribe at any time.

About China Crescent Enterprises, Inc.

China Crescent is a systems integration service provider that markets technology outsourcing services in China including the sale and service of brand name technologies such as Microsoft, Oracle, Cisco, IBM, HP and Dell. Following a strategic acquisition last year, the Company expanded its business line to include original design manufacturing (ODM). China Crescent reported $45 million in profitable revenue in 2009 after reporting over $40 million in revenue for both 2007 and 2008 and has set a goal of reaching $100 million in revenue in 2010.

Headquartered in Dallas with operations in Shanghai, Shenzhen, Dalian and Beijing, China Crescent bridges the gap between global business cultures to assist clients worldwide realize the advantages of the high quality, low cost technology products and services available from China. China Crescent also assists clients in localizing products and services to realize the tremendous growth potential available by expanding into the Chinese Market.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: FNMA - Fannie Mae) LATEST NEWS!! Fannie Mae Announces Semiannual Multifamily Investment Volumes WASHINGTON, July 27, 2010 -- Fannie Mae (OTC Bulletin Board: FNMA) today announced that the company, through its lender and housing partners, provided $5.9 billion in investment to the multifamily rental housing market for the first half of 2010.

"In today's constrained market, Fannie Mae and our Delegated Underwriting and Servicing (DUS(R)) lender partners remain diligent about providing much needed liquidity and stability," said Kenneth Bacon, Executive Vice President of Fannie Mae's Housing and Community Development division. "Despite challenged fundamentals, we are beginning to see an uptick in commitment activity and continue to manage credit risk by maintaining prudent lending standards and asset quality for new loans. Fannie Mae's commitment to sustainability and support of the DUS lenders help us in our efforts to stabilize the market." Fannie Mae Multifamily has bolstered its MBS business since focusing its efforts on securitization and broadening the investor base in 2009. Today, the company provides liquidity to the multifamily market mainly through MBS issuance. Of the $5.9 billion invested in the first half of this year, $5.5 billion was delivered through MBS execution.

The company provides more liquidity to the multifamily market than any other financial institution in the country and continues to serve housing needs of low- to middle-income Americans. In the first half of the year, roughly 90 percent of the rental units financed have been for low and moderate income families.

Fannie Mae exists to expand affordable housing and bring global capital to local communities in order to serve the U.S. housing market. Fannie Mae has a federal charter and operates in America's secondary mortgage market to enhance the liquidity of the mortgage market by providing funds to mortgage bankers and other lenders so that they may lend to home buyers. Our job is to help those who house America.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: BHWX - Black Hawk Exploration Inc.) LATEST NEWS!! Black Hawk Exploration Announces Drill Program Start-up at Dun Glen Gold and Silver Property.

FOX ISLAND, Wash., July 26, 2010 -- Black Hawk Exploration, Inc. (OTC Bulletin Board: BHWX) releases 3rd quarter management report and significant activities and milestones attained over the last 150 day period from March 1, 2010 through current drilling activities at our Dun Glen gold exploration in progress. The Board of Black Hawk Exploration is pleased to announce the mobilization of drilling equipment at our Dun Glen gold and silver property in Nevada. Our focus is to elevate Dun Glen to the status of being one of Nevada's premier gold and silver mines. Newmont Mining estimated Dun Glen contained 500,000 to 2,000,000 ounces of gold in addition to the silver deposits.

In April 2010, the Summary Report with Recommendations for the Dun Glen Gold and Silver Project, was completed by Hunsaker Inc., our consulting geologist. This FREE REPORT is available by emailing [email protected] The following recaps our last 5 months major milestones: 07 26 2010 Dun Glen Drilling Program Commences Today.

07 19 2010 Black Hawk Receives Coarse Gold Results From Dun Glen Project.

07 15 2010 Black Hawk Exploration Files SEC form 10-Q Quarterly Report.

07 14 2010 Black Hawk Commences Dun Glen Gold Drill Program July 26th, 2010.

07 06 2010 Black Hawk Receives Positive Results from Dun Glen Gold Assays.

06 28 2010 Black Hawk Ships Additional Samples from Dun Glen Gold and Silver Claims.

06 23 2010 Black Hawk Exploration to Engage ALS Minerals for Phase 2 Dun Glen Gold Assays.

06 17 2010 Black Hawk Exploration to Release Summary Report with Recommendations for Dun Glen Project.

06 14 2010 Black Hawk Exploration Receives Notice of Acceptance of Environmental Bond Financial Guarantee for Phase 2 Dun Glen Gold Drilling Exploration.

05 14 2010 Black Hawk Receives Additional $200,000 Investment from European Financial Institution.

Golden Black Hawk / Dun Glen Update As the property has passed from one group to another, exceptional research has been done to produce a consolidated analysis of the overall potential of Golden Black Hawk's holdings at Dun Glen. Future cash flows lay on the recovery of precious metals from the surface of the Auld Lang Syne, Black Hole, Monroe and our other 5 mine dumps. Cumulatively the three dumps examined contain approximately 50,000 tons of material and 100,000 tons total with inclusion of all 8.

Drilling commenced today based on Golden Black Hawk's earlier field review and evaluation. The previous results showed the surface grades and potential tonnage are significant enough to warrant analyzing the dumps in more detail and to extend the drilling to the remaining five dumps. The drill program will take approximately 2 to 3 days. Analysis of the samples will be available within 10 days to 2 weeks of completion. Testing will consist of conventional geochemical analysis as well as coarse gold analysis.

Blue Lithium Energy Inc. / Clayton Valley Update Originally focused on the acquisition, exploration and development of a portfolio of strategic lithium properties in the United States and Canada, Black Hawk Exploration acquired a 56 claim, 1120 acres lease in the prolific lithium brine Clayton Valley Nevada, home to the only producing lithium brine mine in the U.S. The results of our initial exploration discovered over 450 feet of lithium brines but the numbers were less than economical at current prices. Plans for our continued exploration at Clayton Valley will be shared with you in early September, 2010.

Over the next 6 months management will maximize the growth of our lithium focus. Blue Lithium Energy is in the earliest stages of discussion and review of additional acquisitions and a potential lithium joint venture. BHWX is committed to a long term development of Blue Lithium Energy. Lithium is the future of efficient energy storage and we plan on being at the center of this growth industry.

About Black Hawk Exploration, Inc.: Black Hawk is a diversified metals and energy exploration company with its current focus on gold and silver discovery through its Dun Glen holdings. Black Hawk is committed to an aggressive program of value added property acquisition, project generation, asset diversity and building Shareholder value. "We are expanding our future lithium, gold and silver growth plans and have confidence we will have funding for a major corporate expansion in the coming months," stated Kevin M. Murphy CEO.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: MLSS - Milestone Scientific Inc.) LATEST NEWS!! Milestone Scientific's STA Single Tooth Anesthesia System(R) Named as One of Dentistry Today's 'Top 100 Products' for Third Consecutive Year LIVINGSTON, N.J., July 27, 2010 -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced, computer-controlled injection technologies, today announced that the Company's patented, award-winning STA Single Tooth Anesthesia System(R) has again been distinguished as one of the "Top 100 Products" of the year by Dentistry Today, the nation's leading clinical news magazine for dentists.

For the past 24 years, Dentistry Today has recognized the industry's leading dental products through its "Top 100 Products" awards program. The "2010 Top 100 Products" marks the third consecutive year that the STA Single Tooth Anesthesia System has been honored as a winning technology. As such, the STA Single Tooth Anesthesia System has been featured in the special Top 100 section of the publication's July issue.

Leonard Osser, Chief Executive Officer of Milestone, stated, "We're very proud to have our STA Single Tooth Anesthesia System again recognized as one of the dental market's leading technologies by one of the industry's most respected publications. The sheer volume of awards that the STA Single Tooth Anesthesia System has won over the past three years is unprecedented in our Company's 15-year history and has served to support our objective of establishing the instrument as the new global standard of care for painless dental injections." The STA Single Tooth Anesthesia System takes the guesswork out of the administration of anesthetic by providing real-time visual and audible feedback via Milestone's portfolio of patented technologies for subcutaneous drug delivery for medical and dental applications. The instrument utilizes Milestone's patented CompuFlo(R) technology with DPS Dynamic Pressure Sensing(R) for the painless delivery and aspiration of all medicaments. During an injection using the STA Single Tooth Anesthesia System, continuous monitoring of the exit pressure of the anesthetic enables a predictable and painless "Single Tooth Anesthesia" to be performed, something that was never before possible using conventional techniques. The benefits of administering injections with the instrument are significant for the patient, the dentist and the business of Dentistry.

About Milestone Scientific Inc.

Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering advanced computer-controlled injection technologies for the medical and dental markets; and currently sells its award-winning products through a global distribution network serving North America, Asia, Africa and Europe. For more information on the STA Single Tooth Anesthesia System(R) and other innovative Milestone products, please visit the Company's web sites found at www.milestonescientific.com ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: AGEN - Antigenics, Inc.) LATEST NEWS!! Antigenics Presents Positive, Top Line Data from Phase I Herpes Clinical Trial Novel, Multi-Valent, HSV-2 Therapeutic Vaccine Generates CD4+ and CD8+ Immune Responses SALT LAKE CITY, Jul 27, 2010 -- Antigenics (NASDAQ: AGEN) announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2 (HSV-2), the virus that causes genital herpes, in infected patients. Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells.

"I believe these data represent the first finding of their kind in genital herpes treatments--showing a vaccine, AG-707, elicits both CD4+ and CD8+ T-cell responses in humans," said David Koelle, M.D., study investigator and professor of Medicine, Laboratory Medicine and Global Health Medicine, University of Washington. "We are very encouraged by these results. Recent data suggest both of these arms of immunity are needed for successful treatment of genital herpes." Data will be presented at the International Herpes Workshop annual meeting in Salt Lake City, Utah, on July 27 by study investigator, Dr. Koelle. The full data will be submitted for publication in a peer-reviewed journal.

"The obvious potential of AG-707 is in managing outbreaks and disease transmission in patients with genital herpes," added Koelle. "Being able to impact and possibly decrease the spread of genital herpes would be a huge step in stemming this epidemic." "These results represent proof of concept for our proprietary off-the-shelf infectious disease platform. Based on our technology of integrating heat shock proteins with antigenic peptides, we could potentially create therapeutic vaccines for many infectious diseases. Our next step is to engage a partner to advance the clinical development of AG-707 in genital herpes and to pursue the broader application of the platform technology," added Garo Armen, PhD, Antigenics chairman and CEO.

STUDY RESULTS In this four-arm, phase 1 study, 35 HSV-2 seropositive patients received AG-707+QS-21 Stimulon(R) adjuvant (Antigenics proprietary saponin adjuvant), AG-707 alone, QS-21 alone, or placebo. Patients received three treatments at two-week intervals. The vaccine was well tolerated, with injection site pain as the most common reported adverse event.

All patients who were evaluable for immune response and received AG-707 with QS-21 showed a statistically significant CD4+ T cell response (100%; 7/7) to HSV-2 antigens as detected by IFN Elispot, and the majority of those patients demonstrated a CD8+ T cell response (63%; 5/8).

This study is the first to demonstrate that heat shock proteins complexed to viral antigens induce an antigen-specific T cell response in humans.

ABOUT HERPES According to the Centers for Disease Control, genital herpes affects more than 60 million Americans--or 1 in 6 people between ages 14 and 49--with an additional 1.5 million new cases each year.(1) This disease normally results in 6 outbreaks per year, but in severe cases more episodes may result.(2) The psychosocial consequences of genital herpes are quite significant, as 57 percent of those infected indicated that herpes had interfered with their sexual relationships, 50 percent felt it was difficult to live with genital herpes, and 37 percent felt that herpes had ruined their lives.(3) Additionally, ongoing research indicates an increasing resistance to currently available genital herpes treatments.

ABOUT AG-707 AG-707 is an off-the-shelf therapeutic vaccine for the treatment of genital herpes, which is caused by the herpes simplex virus-2 (HSV-2). The vaccine is based on Antigenics' heat shock protein (HSP) platform technology. Heat shock proteins (HSPs), also called stress proteins, are found in all cells (normal cells, cancer cells and infected cells) and recent research has demonstrated that HSPs play an essential role in the presentation of pieces of proteins (or peptides) on the cell surface to help the immune system recognize diseased cells. While the initial focus of development has been in HSV-2, the HSP technology platform can potentially be utilized for off-the-shelf treatment of many types of infectious diseases such as HPV, HIV, hepatitis, malaria and tuberculosis.

AG-707 consists of recombinant human heat shock protein-70 complexed with 32 distinct 35-mer synthetic peptides from the HSV-2 proteome. This broad spectrum of herpes antigens is intended to allow for more accurate immune targeting and surveillance, reducing the likelihood of immune escape. Further, the diversity of antigens in AG-707 increases the chance of providing efficacy for a wide segment of the patient population.

ABOUT QS-21 QS-21 is a vaccine adjuvant designed to strengthen the body's immune response to a vaccine's antigen, thus making it more effective. QS-21 has become a critical component in the development of investigational preventive vaccine formulations across a wide variety of infectious diseases, and appears to be essential for several investigational therapeutic vaccines intended to treat cancer and degenerative disorders. Currently, QS-21 is being studied in clinical trials in approximately 15 vaccine indications, of which several are in late-stage clinical trials by Antigenics' licensees, including GlaxoSmithKline and Janssen Alzheimer Immunotherapy, a wholly owned subsidiary of Johnson & Johnson.

ABOUT ANTIGENICS Antigenics (NASDAQ: AGEN) is a biotechnology company working to develop treatments for cancers and infectious diseases. For more information, please visit www.antigenics.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockHunter.us StockHunter.us is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockHunter.us. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

((Comments on this story may be sent to [email protected])) (c) 2010 M2 COMMUNICATIONS

[ Back To TMCnet.com's Homepage ]